ArticleAbdominal radiology (New York)2026
Multimodal AI for early prediction of adverse clinical outcomes in acute pancreatitis.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
21 authors.
Funding
Abstract
backgroundConventional clinical scoring systems and contrast-enhanced computed tomography (CECT) interpretation provide limited accuracy in predicting adverse outcomes in early acute pancreatitis (AP). This leads to suboptimal patient management and underscores the need for improved triage methods. To address this, we developed a multimodal artificial intelligence (AI) framework that integrates clinical parameters, radiomics, and deep learning (DL) models to predict adverse clinical outcomes in early AP.
methodsIn this retrospective tertiary-care, imaging-enriched cohort study, patients with AP who underwent CECT within 72 h of hospital admission were included. Adverse clinical outcomes were defined as mortality, intensive care unit (ICU) admission, or the need for invasive intervention within 30 days. Radiomics (using both pancreatic and peripancreatic features) and DL models were developed using CECT images to predict adverse outcomes. Multimodal models were constructed by integrating imaging and laboratory variables. Model performance was compared with three independent radiologists' prognostic imaging assessments and with established clinical scoring systems (Ranson and Glasgow-Imrie).
resultsA total of 284 patients with AP were included, of whom 140 (49.3%) experienced adverse clinical outcomes. Conventional clinical scores showed limited discrimination, with AUCs of 0.61 for Ranson and 0.67 for Glasgow-Imrie. Imaging-only assessment by three expert radiologists yielded modest predictive performance (average AUC = 0.629; sensitivity = 42.5%, specificity = 83.2%) and moderate interobserver agreement (Fleiss κ = 0.650; ICC = 0.653). Imaging-only radiomics and DL models achieved higher discrimination (AUC 0.77 and 0.76, respectively). Integration of laboratory parameters into the radiomics model further improved predictive performance (AUC of 0.77 to 0.80), whereas the DL and fusion models showed no substantial improvement.
conclusionOur multimodal AI framework, which combines quantitative CECT features with clinical data, enhances the ability to predict adverse outcomes in early AP compared to traditional clinical and imaging severity scoring systems. These findings should be interpreted as preliminary, and prospective multicenter validation is required before considering clinical implementation.
Indexed as
Identifiers
42228172What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.